STEMIRAC report forecasts spinal cord injury sales across seven markets through 2034

Sep 9, 2026 09:57 (46d ago)

Verifying

ResearchAndMarkets.com added a report evaluating Nipro’s STEMIRAC spinal cord injury therapy.
STEMIRAC received conditional, time-limited Japanese marketing authorization in December 2018.
Nipro submitted an application for full marketing approval in November 2025.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.